<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To determine the incidence of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancers</z:e> after bone marrow transplantation, we reviewed the records of <z:hpo ids='HP_0000001'>all</z:hpo> patients at our center who received allogeneic, syngeneic, or autologous transplants for <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 1926) or <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n = 320) </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-five patients were given a diagnosis of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancer</z:e> between 1.5 months and 13.9 years (median, 1.0 year) after transplantation </plain></SENT>
<SENT sid="2" pm="."><plain>Sixteen patients had non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 6 had <z:hpo ids='HP_0001909'>leukemias</z:hpo>, and 13 had <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (including 3 each with <z:hpo ids='HP_0100843'>glioblastoma</z:hpo>, <z:hpo ids='HP_0002861'>melanoma</z:hpo>, and <z:hpo ids='HP_0002860'>squamous-cell carcinoma</z:hpo>) </plain></SENT>
<SENT sid="3" pm="."><plain>There were 1.2 secondary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> per 100 exposure-years during the first year after transplantation (95 percent confidence interval, 0.7 to 2.0) </plain></SENT>
<SENT sid="4" pm="."><plain>The rate declined to 0.4 (95 percent confidence interval, 0.2 to 0.7) after one year </plain></SENT>
<SENT sid="5" pm="."><plain>The age-adjusted incidence of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancer</z:e> was 6.69 times higher than that of primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in the general population </plain></SENT>
<SENT sid="6" pm="."><plain>In a multivariate model, the predictors (and relative risks) of any type of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancer</z:e> were <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> treated with either antithymocyte globulin (relative risk, 4.2) or an anti-CD3 monoclonal antibody (13.6) and total-body irradiation (3.9) </plain></SENT>
<SENT sid="7" pm="."><plain>Two additional factors were associated with secondary non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>: T-lymphocyte <z:mpath ids='MPATH_63'>depletion</z:mpath> of donor marrow (12.4) and HLA mismatch (3.8) </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that recipients of bone marrow transplantation have a low but significant risk of a <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancer</z:e>, particularly non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>